Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announced today that it will attend the BIO International Convention (“BIO”) from June 22-25, 2026, in San Diego, CA. The company’s participation follows last year’s 2025 BIO convention, which served as a catalyst for a greatly expanded business development (“BD”) program that is now starting to deliver positive results. Lexaria intends to build upon this momentum at this year’s conference.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
BIO is the largest convention of its kind, with over 20,000 attendees expected from all corners of the global pharmaceutical and biotechnology industries, as well as supporting sectors such as investors and finance professionals. The conference focuses on intra-industry collaborations and meetings, with over 66,000 partnering meetings having taken place at the 2025 conference. Lexaria has already begun reserving meetings and will be fully booked for the event given the strong industry interest in its proprietary DehydraTECH™ drug delivery platform.
The BIO convention is only the latest example of a multi-faceted BD program that Lexaria quietly launched to inform prospective business partners of the benefits available through DehydraTECH™. Although confidential information cannot be publicly disclosed, Lexaria’s BD program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies, from innovative smaller biotech developers to well-known global pharmaceutical giants.
While Lexaria’s BD program has already developed several ongoing discussions, it continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship, large and small, and ultimately pursue only those that are in the best interests of its shareholders. Additional information will be made available when appropriate.
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. The technology has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.
This announcement is significant as it signals Lexaria’s continued efforts to expand partnerships and commercialize its DehydraTECH platform, which could have broad implications for improving oral drug delivery across multiple therapeutic areas. The high level of interest from both small biotech firms and global pharmaceutical giants underscores the potential impact of this technology on the industry.
